Frazier Life Sciences Adds Experienced Biopharmaceutical Executive to Team
MENLO PARK, CALIF.--(Business Wire / Korea Newswire)--Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive.
Mr. Mikkelsen founded Ascendis Pharma (NASDAQ: ASND) and currently serves as full-time President and Chief Executive Officer, as well as a board member. He previously served as President and Chief Executive Officer of LifeCycle Pharma A/S (acquired by Asahi Kasei Pharma), as well as President of the Pharmaceutical Division of Maxygen, Inc. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S (acquired by Maxygen, Inc.), where he served as Co-Chief Executive Officer. He has also held various positions at Novo Nordisk A/S, including Vice President of Protein Discovery. In addition, Mr. Mikkelsen serves as Chairman of the board of directors for Hummingbird Bioscience.
Mr. Mikkelsen received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark, and pursued his post-doctoral research at Children’s Hospital in Oakland, CA.
“I have known Jan for many years and am very excited to have him join Frazier,” said Managing Partner Albert Cha. “He is a highly experienced biopharmaceutical executive, and we look forward to working with him to identify and evaluate attractive life sciences investment opportunities.”
About Frazier Life Sciences
Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise over $3.3 billion in capital raised, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, 62 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.
For more information about Frazier Life Sciences, please visit www.frazierls.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005286/en/
Frazier Life Sciences
This is a news release distributed by Korea Newswire on behalf of this company.